open access
A New Face of Aldosterone
open access
Abstract
Because aldosterone appears to be a relevant risk factor for cardiovascular disease, the use of aldosterone blockers could provide benefit in the treatment of hypertensive endorgan damage.
In animal models aldosterone blockade attenuates cardiac fibrosis, aortic fibrosis, improves large arterial compliance and protects endothelial function. Hemodynamic and humoral actions of aldosterone have important clinical implications for the use of aldosterone blockers in hypertension and cardiovascular and renal diseases.
Clinical trials have shown that spironolactone reduces cardiac and vascular collagen turnover, reduces ventricular arrhythmias and dilates blood vessels. Aldosterone blockers are effective in the therapy of hyperaldosteronism.
In a clinical study of congestive heart failure - RALES - spironolactone when given in addition to conventional therapy reduced mortality and heart failure hospitalizations as compared to placebo. In recent studies new selective aldosterone blocker - eplerenone - effectively lowered blood pressure in patients with essential hypertension, reduced left ventricular hypertrophy and exerted beneficial effect in patients with post-myocardial left ventricular dysfunction.
Abstract
Because aldosterone appears to be a relevant risk factor for cardiovascular disease, the use of aldosterone blockers could provide benefit in the treatment of hypertensive endorgan damage.
In animal models aldosterone blockade attenuates cardiac fibrosis, aortic fibrosis, improves large arterial compliance and protects endothelial function. Hemodynamic and humoral actions of aldosterone have important clinical implications for the use of aldosterone blockers in hypertension and cardiovascular and renal diseases.
Clinical trials have shown that spironolactone reduces cardiac and vascular collagen turnover, reduces ventricular arrhythmias and dilates blood vessels. Aldosterone blockers are effective in the therapy of hyperaldosteronism.
In a clinical study of congestive heart failure - RALES - spironolactone when given in addition to conventional therapy reduced mortality and heart failure hospitalizations as compared to placebo. In recent studies new selective aldosterone blocker - eplerenone - effectively lowered blood pressure in patients with essential hypertension, reduced left ventricular hypertrophy and exerted beneficial effect in patients with post-myocardial left ventricular dysfunction.
Keywords
aldosterone; aldosterone antagonists; biological activity; cardiovascular risk; congestive heart failure; hypertension
Title
A New Face of Aldosterone
Journal
Issue
Article type
Review paper
Pages
271-279
Published online
2003-09-24
Page views
1120
Article views/downloads
1644
Bibliographic record
Nadciśnienie tętnicze 2003;7(4):271-279.
Keywords
aldosterone
aldosterone antagonists
biological activity
cardiovascular risk
congestive heart failure
hypertension
Authors
Tomasz Dobrucki
Andrzej Januszewicz
Dariusz Sitkiewicz
Włodzimierz Januszewicz